Urticaria in COVID-19 Patient Treated with Lopinavir / Ritonavir : A Case Report
DOI:
https://doi.org/10.66344/jpad.31.4.2021.1773Abstract
The unknown pneumonia was first found in Wuhan, China in December 2019. A novel corona virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated from lower respiratory tract swab in infected patient. The disease caused by this novel virus was then named as COVID-19 (Coronavirus Disease 2019). We report a male patient with urticarial lesions, varies on size and shape on the both arms and both legs and diagnosed with COVID-19 confirmed case. He was treated with powdered oral medicine containing combination of lopinavir and ritonavir. He developed urticarial lesions in three hours after administration of the drug. The lesions then dissapeared and resolved after 4 days of treatment using cetirizine. The conclusion of this case is still needed to be proven whether the urticarial lesion is related to COVID-19 or drugs used for COVID-19 therapy.
Keywords: COVID-19, urticarial drug eruption, lopinavir, ritonavir, infectious disease.
Downloads
Published
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
